MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317200 | Name: Arformoterol tartrate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Arformoterol tartrate is a long acting beta-adrenoceptor agonist drug indicated for the treatment of chronic obstructive pulmonary disease (COPD). It is sold by Sunovion, under the trade name Brovana, as a solution of arformoterol tartrate to be administered twice daily (morning and evening) by nebulization. It is the active (R,R)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.

Chemical Structure

Arformoterol tartrate
Arformoterol tartrate
CAS#200815-49-2 (tartrate)

Theoretical Analysis

MedKoo Cat#: 317200

Name: Arformoterol tartrate

CAS#: 200815-49-2 (tartrate)

Chemical Formula: C23H30N2O10

Exact Mass: 0.0000

Molecular Weight: 494.50

Elemental Analysis: C, 55.87; H, 6.12; N, 5.67; O, 32.35

Price and Availability

Size Price Availability Quantity
100mg USD 650.00 2 Weeks
250mg USD 1,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1254575-18-2 (maleate) 1254710-01-4 (HCl) 200815-49-2 (tartrate)
Synonym
(R,R)-Formoterol; Arformoterol tartrate
IUPAC/Chemical Name
N-[2-Hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-formamide (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt)
InChi Key
FCSXYHUNDAXDRH-OKMNHOJOSA-N
InChi Code
InChI=1S/C19H24N2O4.C4H6O6/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-1(3(7)8)2(6)4(9)10/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2,5-6H,(H,7,8)(H,9,10)/t13-,19+;1-,2-/m11/s1
SMILES Code
O=CNC1=CC([C@@H](O)CN[C@H](C)CC2=CC=C(OC)C=C2)=CC=C1O.O=C(O)[C@H](O)[C@@H](O)C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 494.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Cazzola M, Hanania NA, Matera MG. Arformoterol tartrate in the treatment of COPD. Expert Rev Respir Med. 2010 Apr;4(2):155-62. doi: 10.1586/ers.10.16. PMID: 20406080. 2: Arformoterol: (R,R)-eformoterol, (R,R)-formoterol, arformoterol tartrate, eformoterol-sepracor, formoterol-sepracor, R,R-eformoterol, R,R-formoterol. Drugs R D. 2004;5(1):25-7. doi: 10.2165/00126839-200405010-00004. PMID: 14725487. 3: Madaan A. Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9. doi: 10.1358/dot.2009.45.1.1313983. PMID: 19271027. 4: Donohue JF, Hanania NA, Make B, Miles MC, Mahler DA, Curry L, Tosiello R, Wheeler A, Tashkin DP. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014 Dec;146(6):1531-1542. doi: 10.1378/chest.14-0117. PMID: 25451347; PMCID: PMC4251615. 5: Donohue JF, Ganapathy V, Bollu V, Stensland MD, Nelson LM. Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year. Clin Ther. 2017 Jan;39(1):66-74. doi: 10.1016/j.clinthera.2016.11.021. Epub 2016 Dec 20. PMID: 28011247. 6: Bonasia P, Cook C, Cheng Y, Ong S. Compatibility of arformoterol tartrate inhalation solution with three nebulized drugs. Curr Med Res Opin. 2007 Oct;23(10):2477-83. doi: 10.1185/030079907X233106. PMID: 17784997. 7: Kharidia J, Fogarty CM, Laforce CF, Maier G, Hsu R, Dunnington KM, Curry L, Baumgartner RA, Hanrahan JP. A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008 Aug;21(4):657-62. doi: 10.1016/j.pupt.2008.03.003. Epub 2008 Apr 7. PMID: 18501650. 8: Bollu V, Ernst FR, Karafilidis J, Rajagopalan K, Robinson SB, Braman SS. Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2013;8:631-9. doi: 10.2147/COPD.S52557. Epub 2013 Dec 5. PMID: 24353413; PMCID: PMC3858026. 9: Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007 Feb;29(2):261-78. doi: 10.1016/j.clinthera.2007.02.009. PMID: 17472819. 10: Celli BR, Navaie M, Xu Z, Cho-Reyes S, Dembek C, Gilmer TP. Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment. Int J Chron Obstruct Pulmon Dis. 2019 May 15;14:1019-1031. doi: 10.2147/COPD.S199251. PMID: 31190787; PMCID: PMC6526678. 11: Op't Holt TB. Inhaled beta agonists. Respir Care. 2007 Jul;52(7):820-32. PMID: 17594727. 12: Edge R, Butcher R. Vibrating Mesh Nebulizers for Patients with Respiratory Conditions: Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jul 12. PMID: 31553547. 13: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Oct;29(8):547-83. PMID: 18040531. 14: Bayes M, Rabasseda X, Prous JR. Gateways to Clinical Trials. Methods Find Exp Clin Pharmacol. 2002 Apr;24(3):159-84. PMID: 12087878. 15: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 May;32(4):247-88. doi: 10.1358/mf.2010.32.4.1507200. PMID: 20508873. 16: Kirsch L, Zhang S, Muangsiri W, Redmon M, Luner P, Wurster D. Development of a lyophilized formulation for (R,R)-formoterol (L)-tartrate. Drug Dev Ind Pharm. 2001 Jan;27(1):89-96. doi: 10.1081/ddc-100000132. PMID: 11247540. 17: Keshishian A, Xie L, Dembek C, Yuce H. Reduction in Hospital Readmission Rates Among Medicare Beneficiaries With Chronic Obstructive Pulmonary Disease: A Real-world Outcomes Study of Nebulized Bronchodilators. Clin Ther. 2019 Nov;41(11):2283-2296. doi: 10.1016/j.clinthera.2019.09.001. Epub 2019 Oct 17. PMID: 31630815. 18: Kurihara H, Fujita S, Mase T. (-)-formoterol, a selective beta 2-adrenoreceptor agonist. Acta Crystallogr C. 1997 Dec 15;53 ( Pt 12):1887-9. doi: 10.1107/s0108270197009918. PMID: 9431660. 19: Akapo S, McCrea C, Gupta J, Roach M, Skinner W. Chiral HPLC analysis of formoterol stereoisomers and thermodynamic study of their interconversion in aqueous pharmaceutical formulations. J Pharm Biomed Anal. 2009 Apr 5;49(3):632-7. doi: 10.1016/j.jpba.2008.12.004. Epub 2008 Dec 13. PMID: 19150186.